companydata.dkSalient Pharma ApS: Financial statements 2018
CVR: 36900709
Salient Pharma ApS (CVR 36900709) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -837,788 and a net result of DKK -710,176 compared with DKK -970,745 the year before. Equity amounted to DKK 2,769,481. The solvency ratio was 97%.
- Gross Profit
- -837,788 kr.
- Profit/Loss
- -710,176 kr.
- Equity
- 2,769,481 kr.
- Total Assets
- 2,856,440 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | -838 t. | -710 t. | 2.8 mio. | - |
| 2017 | - | -1.2 mio. | -971 t. | -1.8 mio. | - |
| 2016 | - | -955 t. | -772 t. | -847 t. | - |
Keep an eye on Salient Pharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2018
As of August 31, 2018, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Salient Pharma ApS.
As of August 31, 2018, Søren Wang Petersen has joined the board of directors of Salient Pharma ApS.
As of August 31, 2018, Helle Bøwadt has joined the board of directors of Salient Pharma ApS.
As of August 31, 2018, Søren Johannes Kjær Henningsen has joined the board of directors of Salient Pharma ApS.
Salient Pharma ApS has published its annual report for 2017. Gross profit came to DKK -1,244,332, and the net result was DKK -970,745.
About Salient Pharma ApS
Salient Pharma ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Ulrik Spork. The company is owned by HB-MEDICAL HOLDING ApS, CAND.PHARM. POVL M. ASSENS FOND and SPORCON LIFESCIENCE ADVISORS ApS. In 2025, the company reported a gross profit of DKK -129,889 and a net result of DKK -218,345 compared with DKK -202,180 the year before. Equity amounted to DKK -1,344,010.